You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The agency reviewed data showing that HRD-positive patients on the olaparib/bevacizumab combination had median progression-free survival of 37.2 months.
As GenomeWeb reports, the Food and Drug Administration has issued an Emergency Use Authorization for a CRISPR-based test for SARS-CoV-2.
Increased revenues in the company's life science segment due to demand for its COVID-19-related products drove Meridian's overall growth.
The system is approved for use with the Procleix Ultrio Elite Assay, the Procleix WNV Assay, Procleix Zika Virus Assay, and the Procelix Babesia Assay.
The kit is designed to detect viral RNA extracted from various respiratory samples including sputum, providing results within three and a half hours.
Danaher President and CEO Thomas Joyce will retire in September and will be replaced by Rainer Blair, the current executive VP of the life sciences division.
The company said its test, which provides results in approximately one hour, is the first instance of CRISPR technology being authorized by the FDA.
The firm reported that revenues from screening products rose 35 percent year over year to nearly $220 million.
The oral MET inhibitor, marketed as Tabrecta, is for patients whose tumors have a mutation that leads to MET exon 14 skipping as detected by a Foundation Medicine test.
With new guidance, the US Food and Drug Administration tightens its oversight of SARS-CoV-2 antibody tests.
NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.
Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.